Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) is a phase 2, interventional study registered as NCT06455124 by Fudan University, with a registry enrolment figure of 60 participants, started 2024-05-08 and due to reach its primary completion in 2026-06-30. Interventions recorded: Radiation; PD-1 antibody; Capecitabine; Oxaliplatin. Conditions listed: Rectal Cancer. Primary outcome: 3y LRFS. Colorectal eligibility wording from the registry: "pT1 after local excision of the primary rectal cancer, with at least one of the high-risk features including margin positivity/very close margin (\<1mm) at time of local excision, depth of invasion \>1 mm or SM3 invasion (submucosal invasion to the lower third of the submucosal level), high grade or". Sites: China. No results are recorded here; the registry entry is the source.